ArticleJournal of translational medicine2004
Antiangiogenic gene therapy of cancer: recent developments.
Article in Journal of translational medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 109 citations in OpenAlex.
- Endostatin, chronic kidney disease (CKD) and anemia among older people: a secondary analysis of the screening for CKD among older people across Europe (SCOPE) study.Journal of translational medicine · 2026Article
- Exploring the molecular role of endostatin in diabetic neuropathy.Molecular biology reports · 2021Review
- An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82.Cell death and differentiation · 2020Article
- Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer.International journal of molecular sciences · 2020Review
- Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.International journal of molecular sciences · 2018Review
- Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.Journal of cellular and molecular medicine · 2018Article
- Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.Clinical and experimental immunology · 2017Article
- Multimodal Assessment of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications.Theranostics · 2017Article
- Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- KSHV-Mediated Angiogenesis in Tumor Progression.Viruses · 2016Review
- A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.Lab on a chip · 2015Article
- Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.World journal of gastroenterology · 2014Review
- Anti-angiogenic potential of an ethanol extract of Annona atemoya seeds in vitro and in vivo.BMC complementary and alternative medicine · 2014Article
- Suppression of peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer.International journal of medical sciences · 2014Article
- Is cancer gene therapy an empty suit?The Lancet. Oncology · 2013Review
- In vitro targeted gene electrotransfer to endothelial cells with plasmid DNA containing human endothelin-1 promoter.The Journal of membrane biology · 2013Article
- Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.PloS one · 2013Article
- Update on oncolytic viral therapy - targeting angiogenesis.OncoTargets and therapy · 2013Article
- Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo.BMC complementary and alternative medicine · 2012Article
- Anti-angiogenic gene therapy in the treatment of malignant gliomas.Neuroscience letters · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.